Carmustine medac 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
IAIN/0012/G 
This was an application for a group of variations. 
04/01/2024 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
amended 
on 
Annex II and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
Not including batch control/testing 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
T/0011 
Transfer of Marketing Authorisation 
11/10/2023 
15/11/2023 
SmPC, 
Labelling and 
PL 
IAIN/0010 
A.2.a - Administrative change - Change in the 
13/09/2023 
15/11/2023 
SmPC, 
(invented) name of the medicinal product for CAPs 
Labelling and 
PL 
R/0009 
Renewal of the marketing authorisation. 
26/01/2023 
04/05/2023 
SmPC and PL 
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of 
Carmustine Obvius in the approved indications remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IB/0007/G 
This was an application for a group of variations. 
27/10/2021 
29/11/2021 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0008/G 
This was an application for a group of variations. 
20/10/2021 
n/a 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IA/0005 
B.III.1.a.2 - Submission of a new/updated or 
02/10/2020 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
N/0004 
Minor change in labelling or package leaflet not 
02/09/2020 
29/11/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
II/0002 
Extension of indication to include: “carmustine with 
30/04/2020 
03/06/2020 
SmPC, Annex 
Please refer to Scientific Discussion Carmustine Obvius-H-
II, Labelling 
C-4326-II-0002. 
and PL 
or without total body irradiation (TBI), as 
conditioning treatment prior to allogeneic or 
autologous haematopoietic progenitor cell 
transplantation (HPCT) in haematological diseases” 
for Carmustine Obvius; as a consequence, sections 
4.1, 4.2, 4.4 and 4.8 of the SmPC are updated. The 
Package Leaflet is updated in accordance. 
Furthermore, the PI is brought in line with the latest 
QRD template version 10.1. Version 3.2 of the RMP 
has also been submitted. 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
IB/0003 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
29/10/2019 
03/06/2020 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0001 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
09/11/2018 
24/10/2019 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
Page 4/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
